Cargando…

Lineage-Specific Chimerism and Outcome After Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency

Bi-allelic variants in the dedicator of cytokinesis 8 (DOCK8) gene cause a combined immunodeficiency, characterized by recurrent sinopulmonary and skin infections, food allergies, eczema, eosinophilia, and elevated IgE. Long-term outcome is poor given susceptibility to infections, malignancy, and va...

Descripción completa

Detalles Bibliográficos
Autores principales: Raedler, Johannes, Magg, Thomas, Rohlfs, Meino, Klein, Christoph, Vallée, Tanja, Hauck, Fabian, Albert, Michael H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452590/
https://www.ncbi.nlm.nih.gov/pubmed/34080085
http://dx.doi.org/10.1007/s10875-021-01069-5
_version_ 1784570103253172224
author Raedler, Johannes
Magg, Thomas
Rohlfs, Meino
Klein, Christoph
Vallée, Tanja
Hauck, Fabian
Albert, Michael H.
author_facet Raedler, Johannes
Magg, Thomas
Rohlfs, Meino
Klein, Christoph
Vallée, Tanja
Hauck, Fabian
Albert, Michael H.
author_sort Raedler, Johannes
collection PubMed
description Bi-allelic variants in the dedicator of cytokinesis 8 (DOCK8) gene cause a combined immunodeficiency, characterized by recurrent sinopulmonary and skin infections, food allergies, eczema, eosinophilia, and elevated IgE. Long-term outcome is poor given susceptibility to infections, malignancy, and vascular complications. Allogeneic hematopoietic stem cell transplantation is currently the only curative treatment option and has shown promising outcome. The impact of mixed chimerism on long-term outcome is unclear. We reasoned that reversal of disease phenotype would depend on cell lineage-specific chimerism. DOCK8 variants were confirmed by Sanger and/or exome sequencing and immunoblot and/or intracellular flow cytometry. Donor chimerism was analyzed by XY-fluorescence in situ hybridization or quantitative short tandem repeat PCR. Outcome was assessed by laboratory tests, lymphocyte subsets, intracellular DOCK8 protein flow cytometry, T-cell proliferation analysis, and multiparameter immunoblot allergy screening. We report on nine patients, four of whom with mixed chimerism, with a median follow-up of 78 months after transplantation. Overall, we report successful transplantation with improvement of susceptibility to infections and allergies, and resolution of eczema in all patients. Immunological outcome in patients with mixed chimerism suggests a selective advantage for wild-type donor T-cells but lower donor B-cell chimerism possibly results in a tendency to hypogammaglobulinemia. No increased infectious and allergic complications were associated with mixed chimerism. Aware of the relatively small cohort size, we could not demonstrate a consistent detrimental effect of mixed chimerism on clinical outcomes. We nevertheless advocate aiming for complete donor chimerism in treating DOCK8 deficiency, but recommend reduced toxicity conditioning. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10875-021-01069-5.
format Online
Article
Text
id pubmed-8452590
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-84525902021-10-05 Lineage-Specific Chimerism and Outcome After Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency Raedler, Johannes Magg, Thomas Rohlfs, Meino Klein, Christoph Vallée, Tanja Hauck, Fabian Albert, Michael H. J Clin Immunol Original Article Bi-allelic variants in the dedicator of cytokinesis 8 (DOCK8) gene cause a combined immunodeficiency, characterized by recurrent sinopulmonary and skin infections, food allergies, eczema, eosinophilia, and elevated IgE. Long-term outcome is poor given susceptibility to infections, malignancy, and vascular complications. Allogeneic hematopoietic stem cell transplantation is currently the only curative treatment option and has shown promising outcome. The impact of mixed chimerism on long-term outcome is unclear. We reasoned that reversal of disease phenotype would depend on cell lineage-specific chimerism. DOCK8 variants were confirmed by Sanger and/or exome sequencing and immunoblot and/or intracellular flow cytometry. Donor chimerism was analyzed by XY-fluorescence in situ hybridization or quantitative short tandem repeat PCR. Outcome was assessed by laboratory tests, lymphocyte subsets, intracellular DOCK8 protein flow cytometry, T-cell proliferation analysis, and multiparameter immunoblot allergy screening. We report on nine patients, four of whom with mixed chimerism, with a median follow-up of 78 months after transplantation. Overall, we report successful transplantation with improvement of susceptibility to infections and allergies, and resolution of eczema in all patients. Immunological outcome in patients with mixed chimerism suggests a selective advantage for wild-type donor T-cells but lower donor B-cell chimerism possibly results in a tendency to hypogammaglobulinemia. No increased infectious and allergic complications were associated with mixed chimerism. Aware of the relatively small cohort size, we could not demonstrate a consistent detrimental effect of mixed chimerism on clinical outcomes. We nevertheless advocate aiming for complete donor chimerism in treating DOCK8 deficiency, but recommend reduced toxicity conditioning. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10875-021-01069-5. Springer US 2021-06-02 2021 /pmc/articles/PMC8452590/ /pubmed/34080085 http://dx.doi.org/10.1007/s10875-021-01069-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Raedler, Johannes
Magg, Thomas
Rohlfs, Meino
Klein, Christoph
Vallée, Tanja
Hauck, Fabian
Albert, Michael H.
Lineage-Specific Chimerism and Outcome After Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency
title Lineage-Specific Chimerism and Outcome After Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency
title_full Lineage-Specific Chimerism and Outcome After Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency
title_fullStr Lineage-Specific Chimerism and Outcome After Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency
title_full_unstemmed Lineage-Specific Chimerism and Outcome After Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency
title_short Lineage-Specific Chimerism and Outcome After Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency
title_sort lineage-specific chimerism and outcome after hematopoietic stem cell transplantation for dock8 deficiency
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452590/
https://www.ncbi.nlm.nih.gov/pubmed/34080085
http://dx.doi.org/10.1007/s10875-021-01069-5
work_keys_str_mv AT raedlerjohannes lineagespecificchimerismandoutcomeafterhematopoieticstemcelltransplantationfordock8deficiency
AT maggthomas lineagespecificchimerismandoutcomeafterhematopoieticstemcelltransplantationfordock8deficiency
AT rohlfsmeino lineagespecificchimerismandoutcomeafterhematopoieticstemcelltransplantationfordock8deficiency
AT kleinchristoph lineagespecificchimerismandoutcomeafterhematopoieticstemcelltransplantationfordock8deficiency
AT valleetanja lineagespecificchimerismandoutcomeafterhematopoieticstemcelltransplantationfordock8deficiency
AT hauckfabian lineagespecificchimerismandoutcomeafterhematopoieticstemcelltransplantationfordock8deficiency
AT albertmichaelh lineagespecificchimerismandoutcomeafterhematopoieticstemcelltransplantationfordock8deficiency